Health News Releases

  • Today May 17
July 02, 2019 11:37
Terns Pharmaceuticals Appoints Ankang Li, Ph.D., J.D., CFA as Chief Financial Officer
Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis (NASH) and cancer, announced today the
July 02, 2019 09:27
Takeda Completes Sale of Xiidra® to Novartis
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its sale of its Xiidra® (lifitegrast ophthalmic solution) 5% product to Novartis for $3.4 billion
July 02, 2019 09:22
Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan Corporation
Boehringer Ingelheim and Yuhan Corporation today announced a collaboration and license agreement for the development of a first-in-class dual agonist for the treatment of NASH and related liver diseas
June 28, 2019 15:11
Takeda Selects Five New Partnerships for Annual Global Corporate Social Responsibility (CSR) Program, Supporting Disease Prevention to Improve Health in Developing and Emerging Countries
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced the addition of five partners to its Global CSR Program for 2019, which contributes to the long-term health of pe
June 28, 2019 13:51
U.S. Food and Drug Administration Supports Principles of Open Sharing of Data
The U.S. Food and Drug Administration (FDA), an agency within the Department of Health and Human Services, supports the principle of openly sharing data through efforts like the Patient Safety Movemen
June 26, 2019 13:22
Patient Safety Movement Foundation Announces First Curriculum Commitments
To advance the education of healthcare professionals and reduce the number of preventable deaths, the Patient Safety Movement Foundation (PSMF) has developed core curriculum to teach patient safety th
June 25, 2019 13:43
Terns Pharmaceuticals Announces Exclusive Licensing and Collaboration Agreement with GENFIT to Develop and Commercialize Elafibranor in the Greater China Region
Terns Pharmaceuticals, Inc. today announced an exclusive licensing and collaboration agreement with GENFIT (GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of
June 25, 2019 10:14
SpeeDx announce a collaborative agreement with GSK to supply tests and technology
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has signed a collaborative agreement with GSK, to provide a combination of existing tests and custom test development to sup
June 24, 2019 12:00
Teijin Acquires Exclusive Sales Rights in Asia to BARLEYmax®
Teijin Limited announced today that it has reached an agreement with The Healthy Grain Pty. Limited, an Australian venture company, to acquire the exclusive sales rights in Asia to BARLEYmax® non-gene
June 20, 2019 13:24
Japan’s MHLW Approves Invivoscribe’s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo’s Quizartinib for Treatment of Relapsed/Refractory FLT3-ITD AML. Expands Use to Include Specimens Collected in EDTA
Invivoscribe is pleased to announce that on June 5th the Ministry of Health, Labor and Welfare (MHLW) approved our LeukoStrat® CDx FLT3 Mutation Assay as the companion diagnostic for Daiichi Sankyo’s
Ferring Collaboration with Digital Health Innovators WOOM Aims to Help More People Build Families Fa
June 19, 2019 16:12
Ferring Collaboration with Digital Health Innovators WOOM Aims to Help More People Build Families Faster
Ferring Pharmaceuticals and WOOM today announced a collaboration, which aims to improve and shorten the fertility journeys of the one in six couples who have difficulty conceiving.[1] The WOOM ovul
June 18, 2019 10:16
Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors
Boehringer Ingelheim and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) today announce that the first patient has been dosed in the first-in-human Phase 1 clinical trial evaluating BI 7650
June 14, 2019 10:42
Terns Pharmaceuticals Initiates a Phase 1 Clinical Trial of TERN-101
Terns Pharmaceuticals, Inc. today announced the initiation of a Phase 1 clinical trial of TERN-101, an farnesoid X receptor (FXR) agonist, being developed for the treatment of non-alcoholic steatohepa
June 13, 2019 14:24
BioCell Technology Announces BioCell Collagen® Skin Aging Clinical Trial Poster Presentation at ASN Nutrition 2019
BioCell Technology, LLC, a branded dietary ingredient supplier, today announced the presentation of The Effects of Skin Aging Associated with the Use of BioCell Collagen® in Healthy Adult Females: A R
June 12, 2019 10:19
Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance
Following the success of their ongoing alliance, Boehringer Ingelheim and the University of Dundee extend their collaboration to develop new medicines that target and destroy key cancer causing protei
June 12, 2019 09:01
Takeda Provides Update on TOURMALINE-AL1 Phase 3 Trial in AL Amyloidosis
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) today announced that the Phase 3 TOURMALINE-AL1 clinical trial in patients with relapsed or refractory systemic light-chain (AL) amyloidosis
June 11, 2019 14:59
Full data from CAROLINA® outcome trial support long-term cardiovascular safety profile of Trajenta®
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced full data from the CAROLINA® trial demonstrating that Trajenta® (linagliptin) did not increase cardiovascular risk compared to glim
June 11, 2019 13:24
New Analysis Shows Sleep Apnea More Common in Americas than Previously Thought
ResMed (NYSE: RMD) (ASX: RMD) revealed roughly 170 million people across North and South America have sleep apnea, according to a study it presented at the annual SLEEP meeting hosted by the American
June 11, 2019 10:18
New post-hoc analysis shows consistent cardiorenal risk reductions of empagliflozin in a sub-group of adults with type 2 diabetes and chronic kidney disease without overt proteinuria
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced results of a new post-hoc analysis of data from the EMPA-REG OUTCOME® trial. These results indicated that the effect of empag
June 10, 2019 12:00
Bioventus to Co-Develop Next Generation Placental Tissue Product for Knee Osteoarthritis with MTF Biologics
Bioventus, a global leader in orthobiologic solutions, has entered into a development collaboration agreement with MTF Biologics, the world’s largest tissue bank, to co-develop a next generation place
Surgeons using Microsure‘s MUSA during a microsurgical procedure in a patient’s arm
June 10, 2019 11:58
Microsure’s MUSA Microsurgery Robot Receives CE-mark
MUSA is the world’s first surgical robot for open microsurgery. This robotic assistant is clinically and commercially available after the medical device CE-mark was issued by notified body DEKRA recen
June 10, 2019 11:57
US FDA and EMA Accept Applications for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application for ozanimod for the treatment of people with relaps
June 07, 2019 19:17
Joe Kiani Named Honorary Academic by Mexican Academy of Surgery
The Mexican Academy of Surgery (Academia Mexicana de Cirugía A.C.), an advisory body of the Mexican Federal Government, named Joe Kiani an Honorary Academic of the organization. Kiani is the founder o
June 07, 2019 14:54
Otsuka Chemical Succeeded Part of the Cefixime Business from Astellas Pharma
Otsuka Chemical Co., Ltd. (Head office: Chuo-Ku, Osaka; President & Representative Director: Takeharu Harashima; hereinafter “Otsuka Chemical”) announces that it has succeeded part of the Cefixime bus
June 05, 2019 10:54
Takeda Presents Results from Lung Portfolio Including Phase 1/2 Study of TAK-788 in a Rare Form of NSCLC and New Data on Overall Health-Related Quality of Life for ALUNBRIG® (brigatinib)
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that new data for TAK-788 will be presented during an oral session at the 2019 American Society of Clinical Oncology (ASCO) An
25 per page50 per page75 per page100 per page